Bayer's copanlisib meets primary endpoint in Phase II trial to treat iNHL

German chemical and lifesciences firm Bayer has reported positive results from the Phase II CHRONOS-1 clinical trial of copanlisib for the treatment of indolent non-Hodgkin's lymphoma (iNHL) patients.
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news